Location History:
- Madison, CT (US) (2003)
- Madison, NJ (US) (2006 - 2018)
- East Hanover, NJ (US) (2022)
Company Filing History:
Years Active: 2003-2022
Title: The Innovative Contributions of David E. Lebwohl
Introduction
David E. Lebwohl is a prominent inventor based in Madison, Connecticut, known for his significant contributions to the field of cancer treatment. With a total of five patents to his name, he has focused on developing combination therapies that enhance the effectiveness of existing treatments.
Latest Patents
Among his latest patents, one notable invention involves a combination comprising an immunomodulator and a second therapeutic agent for treating cancer. The immunomodulator can be an inhibitor of an immune checkpoint molecule or an activator of a costimulatory molecule. The second therapeutic agent may include options such as a c-MET inhibitor, a CDK4/6 inhibitor, a PI3K inhibitor, a BRAF inhibitor, an FGFR inhibitor, a MEK inhibitor, or a BCR-ABL inhibitor. These combination therapies aim to treat or prevent various cancerous conditions and disorders. Another patent focuses on combination therapies of EGFR inhibitors, which also target cancerous conditions and disorders.
Career Highlights
David has had a distinguished career, working with leading pharmaceutical companies such as Novartis AG and Bristol-Myers Squibb Company. His work has significantly impacted the development of innovative cancer therapies, showcasing his commitment to advancing medical science.
Collaborations
Throughout his career, David has collaborated with notable professionals in the field, including Malte Peters and Peter Wayne Marks. These collaborations have further enriched his research and development efforts.
Conclusion
David E. Lebwohl's innovative work in combination therapies has made a substantial impact on cancer treatment. His patents reflect a deep understanding of the complexities of cancer and a commitment to improving patient outcomes.